<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434941</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2005-01</org_study_id>
    <nct_id>NCT00434941</nct_id>
  </id_info>
  <brief_title>Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours</brief_title>
  <official_title>Multicenter Phase IV.II Trial, for the Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, multicenter phase IV.II study. Patients with local relapse&#xD;
      breast cancer will receive radiotherapy concomitant to the administration of capecitabine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total dose of radiotherapy will be 50 Gy administered in daily session of 200 centigray&#xD;
      (cGy). Radiotherapy treatment will not be longer than 6 weeks.&#xD;
&#xD;
      All patients will receive 1650 mg/m2 by mouth, per day (825 mg/m2 twice a day (p.o. bid) for&#xD;
      35 days.&#xD;
&#xD;
      Tissue samples must be analysed to determinate the human epidermal growth factor receptor-2&#xD;
      (HER2) by fluorescent in situ hybridization (FISH) technical.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the slow rate of recruitment the study was stopped.&#xD;
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clinical response rate</measure>
    <time_frame>28 days after the end of the radiotherapy</time_frame>
    <description>The disease evaluation will be measured by RECIST criteria in the 28 days after the end of the radiotherapy by Magnetic resonance imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the concomitant administration of capecitabine and radiotherapy as the first treatment</measure>
    <time_frame>28 days after the end of the radiotherapy</time_frame>
    <description>Safety will be assessed by standard clinical and laboratory tests. Adverse events grade will be defined by the National Cancer Institute Common Terminology Criteria for Adverse (NCI-CTCAE).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Radiotherapy + Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Radiotherapy + Capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Histological diagnoses of operable invasive adenocarcinoma of the breast.&#xD;
&#xD;
          -  Patients with tumour HER2 negative.&#xD;
&#xD;
          -  Previous mastectomy surgery.&#xD;
&#xD;
          -  Actual diagnoses of local recurrence of breast cancer.&#xD;
&#xD;
          -  Patients must not present evidence of metastatic disease.&#xD;
&#xD;
          -  Age &gt;= 18 years old.&#xD;
&#xD;
          -  Performance status (Karnofsky index) &gt;= 70.&#xD;
&#xD;
          -  Laboratory results (within 14 days prior to randomization):&#xD;
&#xD;
          -  Hematology:&#xD;
&#xD;
               -  neutrophils &gt;= 1.5 x 10e9/l;&#xD;
&#xD;
               -  platelets &gt;= 100x 10e9/l;&#xD;
&#xD;
               -  hemoglobin &gt;= 10 mg/dl&#xD;
&#xD;
          -  Hepatic function:&#xD;
&#xD;
               -  total bilirubin &lt;= 1,5 upper normal limit (UNL);&#xD;
&#xD;
               -  Alanine transaminase (SGOT) and aspartate aminotransferase (SGPT) &lt;= 1.5 UNL;&#xD;
&#xD;
               -  alkaline phosphatase &lt;= 1.5 UNL.&#xD;
&#xD;
          -  Renal Function:&#xD;
&#xD;
               -  creatinine &lt;= 175 µmol/l (2 mg/dl)or creatinine clearance &gt;= 60 ml/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastasis or metastatic disease in organs.&#xD;
&#xD;
          -  Metastasis in internal mammary chain lymph nodes&#xD;
&#xD;
          -  Previous radiation treatment on the breast or other locations (30% or greater of the&#xD;
             bone marrow).&#xD;
&#xD;
          -  Prior treatment with continuous (greater than 24h) 5-fluorouracil (5-FU) infusion,&#xD;
             capecitabine or other oral fluoropyrimidines such as eniluracil/5-FU , uracil/tegafur,&#xD;
             S1 or emitefur.&#xD;
&#xD;
          -  Known hypersensitivity to capecitabine, doxifluridine or any of its components.&#xD;
&#xD;
          -  Organ allografts that require an immunosuppressor therapy.&#xD;
&#xD;
          -  History of neurological or psychiatric disorders, which could preclude the patients to&#xD;
             free informed consent.&#xD;
&#xD;
          -  Clinically significant cardiac disease such as congestive heart failure, symptomatic&#xD;
             coronary artery disease and cardiac arrhythmia not well controlled with medication or&#xD;
             history of myocardial infarction within the last 12 months or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          -  Evidence of central nervous system (CNS) metastases. Pts with a history of&#xD;
             uncontrolled seizures, CNS disorders or psychiatric disability judged by the&#xD;
             investigator to be clinically significant precluding informed consent or interfering&#xD;
             with compliance should be excluded from the study.&#xD;
&#xD;
          -  Pregnant or lactating women. Adequate contraceptive methods must be used during&#xD;
             chemotherapy and hormone therapy treatments. Negative pregnancy test in the 14&#xD;
             previous days to randomization.&#xD;
&#xD;
          -  Active uncontrolled infection or other severe pathologies such as active peptic ulcer,&#xD;
             unstable diabetes mellitus.&#xD;
&#xD;
          -  Major surgery during 4 weeks prior to treatment.&#xD;
&#xD;
          -  Patients lacking physical integrity of upper gastrointestinal tract or with history of&#xD;
             bad absorption syndrome.&#xD;
&#xD;
          -  Anticoagulant treatment with coumadin anticoagulants.&#xD;
&#xD;
          -  Concomitant treatment with other investigational products. Participation in other&#xD;
             clinical trials with a non-marketed drug in the 30 previous days before randomization.&#xD;
&#xD;
          -  Concomitant treatment with other therapy for cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico Universitario San Carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Esperanza</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 13, 2007</study_first_submitted>
  <study_first_submitted_qc>February 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2007</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Administration of capecitabine concomitant to radiotherapy</keyword>
  <keyword>Her2: negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

